Sanofi India Shares Fall 4% After Rodolfo Hrosz Resigns as Non-Executive Director

Sanofi India Limited has announced a change in its board composition with the resignation of Non-Executive Director Rodolfo Hrosz. The development was communicated to the Board through a formal letter dated 24 February 2026. 

Resignation Effective from 28 February 2026 

In his communication to the Board, Hrosz stated that he would be stepping down due to other professional commitments and pre-occupations. The resignation will take effect from the close of business hours on 28 February 2026. 

He clarified that there are no additional reasons behind his decision and expressed appreciation to fellow Board members for their guidance and support during his tenure. 

About Sanofi India  

Sanofi India Limited is the listed Indian arm of the global healthcare major Sanofi. The company focuses on prescription medicines and vaccines across key therapeutic areas, including cardiology, diabetes, and central nervous system disorders. Headquartered in Mumbai, it operates manufacturing facilities in India and markets its products nationwide through an established distribution network. 

Read More: IOL Chemicals Share Price Surges By 3%; Receives EDQM Certificate Of Suitability For Clopidogrel Besilate API!  

Sanofi India Share Price Performance  

As of 26 February 2026, at AM, Sanofi India Ltd share price is trading at  ₹3,965.00 per share, reflecting a decline of 4.10% from the previous closing price. Over the past month, the stock has declined by 3.62%. 

Conclusion 

With Rodolfo Hrosz’s exit taking effect at the end of February 2026, Sanofi India will undergo a board-level change while continuing its operations in the pharmaceutical sector. The company has not indicated any immediate additional changes to its board composition. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.